Immune Responses Similar for Adjuvanted and Standard Dose Influenza Vaccines for Patients with Haematologic Malignancies By Ogkologos - February 4, 2025 541 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a randomised, controlled study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR SIOG 2020: New Research in Caring for and Treating People With... November 12, 2020 EMA Recommends Extending Indications for Pembrolizumab to Include Adjuvant Treatment in... October 6, 2023 Remembering With Gratitude January 7, 2021 Male Patients with Cancer at Higher Risk of Severe Disease Course... August 26, 2020 Load more HOT NEWS Cancer Research UK reports record levels of investment in its spinouts Mortality From PSA-Detected Localised Prostate Cancer Remains Very Low Regardless of... From smouldering ash to a gleaming temple for cancer research: The... Consistent Efficacy Benefit with Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Patients...
